Industry-leading portfolio of water-free ophthalmic therapeutics

What is new about Novaliq’s products?

Novaliq develops first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first and only water-free technology, increasing residual time on the eye and enabling high bio-availability of active pharmaceutical ingredients (API) with excellent tolerability and safety with reduced extra-ocular systemic exposure. EyeSol® unlocks the full potential of APIs by generating novel drug products often with new Composition of Matter IP. The technology is clinically validated, safe and well accepted.

Novalqi CyclASol® Eye Drops


ophthalmic solution of 0.1% cyclosporine A in EyeSol® developed to treat aqueous deficient DED

(investigational drug)

Novaliq NOV03 Eye Drops


first drug developed to treat DED associated with Meibomian gland dysfunction in a highly effective way

(investigational drug)

Novaliq NovaTears® Eye Drops


First-in-class, preservation free eye treatment for tear film stabilization in dry eye.

(available in Europe, Australia and New Zealand)

Novaliq NovaTears®+Omega-3 Eye Drops


First-in-class, preservative-free and clear eye drop containing 0.2% Omega-3 fatty esters.

(coming soon)

What are the benefits of Novaliq’s products?

Clearly differentiated products based on our water-free EyeSol® platform. The key benefits are:

  • Excellent suspendability and solubility of poorly soluble drugs
  • Strong stability enhancement of antibodies, proteins and small molecules
  • Optimal spreading and wetting abilities
  • Strongly enhanced penetration
  • Excellent safety and tolerability profile
  • No preservatives

For which indications are products in development?

Dry Eye Disease (DED), Glaucoma and Retinal Diseases.

What products are next in the pipeline?

  • CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II, for the treatment of moderate to severe DED.
  • NovaTears®+Omega-3 – a first-in-class, preservative-free and clear eye drop containing 0,2% Omega-3. It stabilizes the lipid layer and reduces the evaporation of the underlying water phase of the tear film.

What clinical trials are currently under way?

  • CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II for the treatment of moderate to severe DED (CYS-002).
  • NovaTears® – a first-in-class, preservative free ophthalmic artificial tear for patients with mild to moderate dry eye disease (NT-004).
  • NOV03 – a first-in-class, preservative free drug treatment addressing MGD and evaporative-caused DED (SEECASE-trial).

What are Novaliq’s products?

Novaliq offers an industry-leading portfolio of new, water-free and IP-protected ophthalmic therapeutics with proven market and clinical success.

Start typing and press Enter to search